Ardent Health CEO granted 195,316 shares

Bonick Martin reported acquisition or exercise transactions in this Form 4 filing.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Bonick Martin reported acquisition or exercise transactions in this Form 4 filing.

Ardent Health, Inc. President and CEO Martin Bonick received a grant of 195,316 shares of common stock at no cost as part of his equity compensation. These shares were earned based on 2024 and 2025 performance under performance-vesting restricted stock units awarded on July 18, 2024.

The granted shares will vest on December 31, 2026, contingent on his continued service through that date, meaning he does not fully own them until then. Following this award, Bonick directly holds 1,322,300 shares of Ardent Health common stock.

Insider Trade Summary

Grant/Award: 195,316 shares

Grant/Award 1 txn

Insider Bonick Martin

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	195,316	$0.00	$0.00

Holdings After Transaction: Common Stock — 1,322,300 shares (Direct)

Footnotes (1)

F1. Shares earned based on 2024 and 2025 performance under performance vesting restricted stock units awarded on July 18, 2024. Pursuant to the terms of the award, the shares will vest on December 31, 2026 contingent upon service through such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Ardent Health (ARDT) report for CEO Martin Bonick?

Ardent Health reported that CEO Martin Bonick received a grant of 195,316 shares of common stock as equity compensation. The award was earned based on 2024 and 2025 performance under previously granted performance-vesting restricted stock units.

How many Ardent Health (ARDT) shares were granted to the CEO and at what price?

Martin Bonick was granted 195,316 shares of Ardent Health common stock at a reported price of $0.00 per share, reflecting a compensation award rather than an open-market purchase. The shares stem from performance-based restricted stock units granted on July 18, 2024.

When do Martin Bonick’s new Ardent Health (ARDT) shares vest?

The 195,316 performance-based shares will vest on December 31, 2026. Vesting is contingent on Martin Bonick’s continued service with Ardent Health through that date, so the award is earned over time rather than immediately unrestricted.

Are the Ardent Health (ARDT) shares acquired by the CEO an open-market purchase?

No, the 195,316 shares reported for Martin Bonick are a compensation-related grant, not an open-market purchase. They were earned under performance-vesting restricted stock units and awarded at no cash cost to him, subject to future vesting conditions.

What is Martin Bonick’s Ardent Health (ARDT) ownership after this stock award?

After the reported grant, Martin Bonick directly holds 1,322,300 shares of Ardent Health common stock. This total reflects his position following the addition of the 195,316 performance-based shares subject to vesting on December 31, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/13/2026 - 04:17 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bonick Martin

(Last)

(First)

(Middle)

340 SEVEN SPRINGS WAY, SUITE 100

(Street)

BRENTWOOD

37027

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Ardent Health, Inc. [ ARDT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/11/2026		A		195,316⁽¹⁾	A	$0	1,322,300	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares earned based on 2024 and 2025 performance under performance vesting restricted stock units awarded on July 18, 2024. Pursuant to the terms of the award, the shares will vest on December 31, 2026 contingent upon service through such date.

Remarks:

	/s/ Stephen C. Petrovich, Attorney-in-Fact	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR